Development and License Agreement



 Exhibit 10.9 
  
  
 DEVELOPMENT AND LICENSE AGREEMENT

 dated as of June 3, 2004 
 by and between 
 BIOSPECIFICS TECHNOLOGIES CORP. 
 (a Delaware corporation) 
 and 

 AUXILIUM PHARMACEUTICALS, INC. 
 (a Delaware corporation) 
  
  







 SCHEDULES 
  

			
	Schedule 1.7	  	BTC Patents
	Schedule 1.16	  	Cost of Goods
	Schedule 1.21	  	Enzyme
	Schedule 3.2	  	Clinical Trials

  

 i 








 DEVELOPMENT AND LICENSE AGREEMENT 
 This DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”) dated the 3rd day of June, 2004 (the “June 3, 2004”) is by
and between BioSpecifics Technologies Corp., a corporation organized and existing under the laws of Delaware and having its principal office at 35 Wilbur Street, Lynbrook, New York 11563, and its Affiliates (“BTC”), and Auxilium
Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 160 West Germantown Pike, Norristown, PA 19401 (“Auxilium”). BTC and Auxilium shall sometimes be
referred to herein individually as a “Party” and collectively as “Parties.” 
 INTRODUCTION

 WHEREAS, BTC controls certain BTC Patents and BTC Know-How (each as defined below) related to the Enzyme and the Product (each as
defined below), and has the right to grant certain rights and licenses thereunder as set forth herein, and 
 WHEREAS, Auxilium has certain
expertise in the development and commercialization of pharmaceutical products, and Auxilium wishes to obtain certain licenses and options to develop and commercialize the Product for certain therapeutic uses in humans, and 
 WHEREAS, BTC wishes to convey such licenses to Auxilium. 
 NOW, THEREFORE, in consideration of the mutual promises, covenants and agreements hereinafter set forth, the sufficiency of which is hereby acknowledged, the Parties to this Agreement mutually agree as follows:

 ARTICLE 1 
 DEFINITIONS 
 For purposes of this Agreement, the following initially capitalized terms in this Agreement, whether used in
the singular or plural, shall have the following meanings: 
 1.1 “Additional Indication” shall mean any Indication for a
Product outside of the Field. 
 1.2 “Additional Indication Option” has the meaning set forth in Section 2.2(b).

 1.3 “Adverse Drug Experience” shall mean any of the following as such terms are defined at either 21 C.F.R. § 312.32
or 21 C.F.R. § 314.80: an “adverse drug experience,” a “life-threatening adverse drug experience,” a “serious adverse drug experience,” or an “unexpected adverse drug experience” and the foreign
counterparts thereof. 
 1.4 “Affiliate” shall mean any corporation, company, partnership, joint venture or firm which
controls, is controlled by, or is under common control with a specified person or entity. For purposes of this Section 1.4, “control” shall be presumed to exist if one of the following conditions is met: (a) in the case of
corporate entities, direct or indirect ownership of 








 
at least fifty percent (50%) of the stock or shares having the right to vote for the election of directors, and (b) in the case of non-corporate
entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and policies of such non-corporate entities. The Parties acknowledge that in the case of certain entities
organized under the laws of certain countries outside of the United States, the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and that in such cases such lower percentage shall be
substituted in the preceding sentence, provided that such foreign investor has the power to direct the management and policies of such entity. 
 1.5 “Auxilium Remaining Indication” shall mean an Additional Indication for a Product that Auxilium believes has a reasonable probability of obtaining Regulatory Approval and achieving commercial success, but for which BTC
does not wish to undertake Stage I Development. 
 1.6 “BTC Know-How” shall mean any proprietary information or materials
related to the Manufacture, preparation, formulation, use or development of the Enzyme or the Product Controlled by BTC during the Term and shall include formulations, processes, techniques, formulas, biological, chemical, assay control and
manufacturing, technical, pre-clinical, clinical or other data, methods, know-how, and trade secrets. 
 1.7 “BTC Patents”
shall mean those Patents Controlled by BTC with at least one claim directed to the Enzyme or the Product (or processes, improvements, uses and intermediates for the foregoing) including those listed on Schedule 1.7 attached hereto as it may
be amended from time to time. 
 1.8 “BTC Product” shall mean any pharmaceutical product that includes Enzyme as an active
ingredient and is under development for an Indication (or is indicated for use) outside the Field. 
 1.9 “Business Day”
shall mean any day on which banking institutions in New York, New York are open for business. 
 1.10 “Clinical Trials”
shall mean tests and studies in human subjects or patients that are required to obtain, maintain, or sustain Regulatory Approval in a country in the Territory. 
 1.11 “Commercialization” or “Commercialize” shall mean activities directed to marketing, promoting, co-promoting, distributing, importing, exporting, offering for sale and selling the
Product. When used as a verb, “Commercialize” means to engage in Commercialization. 
 1.12 “Commercially Reasonable
Efforts” means, with respect to a Party, the efforts and resources which would be used by that Party relating to a certain activity or activities, consistent with its normal business practices, which are consistent with the general level of
effort and resources in the pharmaceutical industry for a company similar in size and scope. 
  

 2 








 1.13 “Competing Product” shall mean a product that contains Enzyme and is sold in a
country by a Person (other than Auxilium) in an Indication for which Auxilium is marketing a Product in such country. 
 1.14
“Confidential Information” has the meaning set forth in Section 10.1 
 1.15 “Controlled” or
“Controls”, when used in reference to intellectual property, shall mean the legal authority or right of a Party hereto (or any of its Affiliates) to grant a license or sublicense of intellectual property rights to another Party, or
to otherwise disclose proprietary or trade secret information to such other Party, without breaching the terms of any agreement with a Third Party, infringing upon the intellectual property rights of a Third Party, or misappropriating the
proprietary or trade secret information of a Third Party. 
 1.16 “Cost of Goods” shall mean the total cost of
Product in Final Packaging, including, but not limited to, the sum of the following actual costs: (i) manufacturing, shipping and storage of Enzyme; (ii) manufacturing, shipping and storage of Product, prior to sale to a Third Party;
(iii) commercial packaging and labeling; (iv) routine quality compliance and quality assurance programs; and (v) customs or excise taxes, import duties, sales taxes and other taxes or duties (other than those taxes resulting from
sales to a Third Party of Product in finished packaged and labeled form). In the event that BTC manufactures Enzyme or Products, Cost of Goods shall be calculated in accordance with Schedule 1.16. 
 1.17 “Develop” or “Development” shall mean Stage I Development and Stage II Development. When used as a verb,
“Developing” means to engage in Development. For purposes of clarity, in no event shall Development include Manufacture. 
 1.18 “Development Costs” shall mean costs associated with Development activities. 
 1.19 “Effective
Date” shall mean the date specified in the first paragraph of this Agreement. 
 1.20 “EMEA” shall mean the
European Medicines Evaluation Agency or any successor agency thereto. 
 1.21 “Enzyme” shall mean an enzyme more
particularly described on Schedule 1.21, and any variants or derivatives thereof. 
 1.22 “European Union” shall mean
the countries of the European Union, as it is constituted as of the Effective Date and as it may be expanded from time to time. 
 1.23
“Exercised Indication” has the meaning set forth in Section 2.2(c). 
 1.24 “Exercised Indication
Date” has the meaning set forth in Section 2.2(c). 
 1.25 “Exercise Period” has the meaning set forth in
Section 2.2(c). 
 1.26 “FDA” shall mean the U.S. Food and Drug Administration or its successor agency. 
  

 3 








 1.27 “Field” shall mean, subject to expansion pursuant to Section 2.2, the
prevention or treatment of Dupuytren’s Disease and Peyronie’s Disease. 
 1.28 “Final Packaging” means the
labeling and packaging to be used in connection with the Product labeled for use in the Field in the Territory, including the packaging of package inserts and components reasonably necessary for sale of the finished Product to the ultimate consumer.

 1.29 “Indemnified Party” has the meaning set forth in Section 12.3. 
 1.30 “Indemnifying Party” has the meaning set forth in Section 12.3. 
 1.31 “Indication” shall mean a pharmaceutical application for the Product. 
 1.32 “Infringement Claim” has the meaning set forth in Section 8.2(a). 
 1.33 “Law” shall mean any applicable statute, law, ordinance, regulation, order, or rule of any federal, state, local, foreign, or other
governmental agency or body or of any other type of regulatory body (including common law) or securities exchange, including those covering pharmaceutical sales, environmental, pollution, energy, safety, health, transportation, bribery,
record-keeping, zoning, antidiscrimination, antitrust, wage and hour, and price and wage control matters. 
 1.34 “Licensed
Technology” shall mean the BTC Patents and the BTC aKnow-How. 
 1.35 “Loss” has the meaning set forth in
Section 12.1. 
 1.36 “Major Market Country” shall mean the [**]. 
 1.37 “MAA” shall mean an application seeking Regulatory Approval of the Regulatory Authority in the European Union to market and sell a
Product in the Field in the European Union. 
 1.38 “MAA Acceptance” shall mean the written notification by the applicable
Regulatory Authority that the MAA has met all the criteria for filing acceptance. 
 1.39 “Manufacture” or
“Manufacturing” shall mean manufacturing, filling, processing, testing, engineering, designing, redesigning, packaging, storing, quality control, quality assurance, releasing, disposing, handling, shipping, and all other activities
undertaken or required to be undertaken in order to manufacture and supply the Product in its Final Packaging and related devices and apparatus for administration thereof, in the case of commercial supplies, or packaged in accordance with Laws, in
the case of clinical supplies. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED PURSUANT TO AN ORDER GRANTING CONFIDENTIAL TREATMENT ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.


  

 4 








 1.40 “NDA” or “New Drug Application” shall mean a new drug application
filed with the FDA pursuant to 21 C.F.R. §314, seeking permission to market the Product for a particular Indication in the Field in interstate commerce in the United States. 
 1.41 “NDA Filing Acceptance” shall mean the written notification by the FDA that the NDA has met all the criteria for filing acceptance.

 1.42 “Net Sales” shall mean the gross amount invoiced by Auxilium and its Affiliates or Sublicensees on account of sales
of the Product in Final Packaging to Third Parties in the Territory, less the total of: (a) trade, cash or quantity discounts not already reflected in the amount invoiced; (b) excise, sales and other consumption taxes and customs duties to
the extent included in the invoice price; (c) freight, insurance and other transportation charges to the extent specifically included in the invoice price; (d) returns or retroactive price reductions; and (e) compulsory payments and
rebates directly related to the sale of the Product accrued, paid or deducted pursuant to governmental regulations. 
 1.43 “Orphan
Drug Designation” shall mean the special designation of Product by FDA’s Orphan Product Division which provides the Product with the opportunity to obtain additional market exclusivity from the date the drug receives FDA approval and
also possible tax and regulatory approval benefits. The term “Orphan Drug Designation” shall include any foreign counterparts of the foregoing. 
 1.44 “Patents” shall mean any patents or patent applications and any continuations, continuations-in-part, divisions, provisionals, substitutions, patents of addition, reissues, reexamination,
renewals or extensions thereof (including any supplemental patent certificates) and any confirmation patent or registration patent and all foreign counterparts of any of the foregoing. 
 1.45 “Person” shall mean any individual, corporation, partnership, association, joint-stock company, trust, unincorporated organization
or government or political subdivision thereof. 
 1.46 “Phase II Clinical Trials” shall mean a Clinical Trial for the
Product on a number of patients, no fewer than the number required to allow for the detection of statistical differences between the control and treated patients, for the purposes of determining dose and evaluating safety and efficacy in the
proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same. 
 1.47 “Phase III Clinical Trials” shall mean a Clinical Trial for the Product on sufficient numbers of patients to generate safety and
efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or
concerns raised by the same. 
  

 5 








 1.48 “Product” shall mean pharmaceutical product containing Enzyme as an active
ingredient and any reformulation, improvement, enhancement, combination, refinement, or modification thereof; provided however, Product shall specifically exclude dermal formulations labeled for topical administration. 
 1.49 “Product Data” shall mean the physical embodiment, to the extent available of: (a) the know-how, including relevant laboratory
notebook information, screening data and synthesis schemes, including descriptions in any form, data and other information, and (b) all other data including Regulatory Data and any other pre-clinical and clinical data and information,
technical, chemical, safety and scientific data, information and know-how, obtained or generated in connection with Development of the Product in the Field. 
 1.50 “Product Details” shall mean a face-to-face meeting, in an individual or group practice setting, between a healthcare professional with prescribing authority who is a target prescriber of a
Product in the Field and a professional representative of the applicable Party during which the key attributes of a Product are verbally presented to such healthcare professional. When used as a verb, “detail” or “detailing”
shall mean to engage in a Detail. 
 1.51 “Regulatory Approval” shall mean, with respect to a country or group of countries
in the Territory, all authorizations by the appropriate governmental entity or entities necessary for commercial sale of the Product in the Field for a particular Indication in that country or group of countries including, where applicable, approval
of labeling, price, reimbursement and manufacturing. 
 1.52 “Regulatory Authority” shall mean the FDA or any foreign
counterpart or additional governmental or regulatory agencies in the Territory responsible for applicable Regulatory Approvals. 
 1.53
“Regulatory Data” shall mean any and all research data, pharmacology data, chemistry, manufacturing, and control data, preclinical data, clinical data or all other documentation submitted, or required to be submitted, to Regulatory
Authorities in association with regulatory filings for the Product in the Field (including any Drug Master Files (DMFs), Chemistry, Manufacturing and Control (“CMC”) data, or similar documentation). 
 1.54 “Remaining Indication” shall mean an Additional Indication for which Auxilium has not exercised an Additional Indication Option
within the Exercise Period. 
 1.55 “Stage I Development” shall mean pre-clinical and clinical drug development activities
reasonably necessary to completing all development activities up to and including the completion of Phase II Clinical Trials for the Product in the Field, including pre-clinical studies, test method development, statistical analysis, Clinical
Trials, regulatory affairs, and activities directed to seeking Regulatory Approvals. 
 1.56 “Stage I Development Costs”
shall mean costs associated with Stage I Development activities. 
  

 6 








 1.57 “Stage II Development” shall mean non-clinical and clinical drug development
activities reasonably necessary to the development and submission of Regulatory Data to a Regulatory Authority for the purpose of achieving Regulatory Approval, including non-clinical studies, test method development, statistical analysis, Clinical
Trials, regulatory affairs, and activities directed to seeking Regulatory Approvals. 
 1.58 “Stage II Development Costs”
shall mean costs associated with Stage II Development activities. 
 1.59 “Standard Terms” has the meaning set forth in
Section 6.4(d). 
 1.60 “Sublicense Income” shall mean (a) the upfront payment, if any, actually received from a
Sublicensee by Auxilium upon execution of an agreement with such Sublicensee, and (b) any milestone payments actually received from a Sublicensee by Auxilium in consideration for the grant of a sublicense to such Sublicensee under the Licensed
Technology in the Field; provided, however, that Sublicense Income shall not include any such consideration received by Auxilium from any such Sublicensee in return for, as payment for or otherwise in respect of: (i) equity or debt of Auxilium
(provided, however, that the exclusion contained in this sub-clause (i) shall not apply to transactions between Auxilium and its Affiliates), (ii) the manufacture or supply of ingredients or products, (iii) the performance of services
(including research and development services other than screening services performed on behalf of a Sublicensee) or other similar payments, (iv) reimbursement of Auxilium’s out of pocket costs and expenses, including patent expenses, or
(v) the sale of Auxilium in whole or in part. 
 1.61 “Sublicensee” shall mean a Person to whom Auxilium grants any
right or license to use the Licensed Technology to make, use or sell the Product in the Field in the Territory. 
 1.62 “Supply
Agreement” has the meaning set forth in Section 6.4. 
 1.63 “Term” has the meaning set forth in Section
11.1(a). 
 1.64 “Territory” shall mean all the countries and territories of the world. 
 1.65 “Third Party” shall mean any Person or other entity other than Auxilium, BTC or their respective Affiliates. 
 1.66 “Vial” shall means a single dose unit of Product. 
  


 7 








 ARTICLE 2 
 LICENSE AND OPTION 
 2.1 License Grant to Auxilium 
 (a) Subject to the terms and conditions of this Agreement, on the Effective Date, BTC hereby grants to Auxilium an exclusive license under the Licensed
Technology to research, Develop, use, Commercialize, market, sell and distribute the Product for the Field in the Territory. 
 (b) Subject
to the terms and condition of this Agreement, BTC hereby grants to Auxilium a non-exclusive right and license under the Licensed Technology to Manufacture or have Manufactured the Product for the Field in the Territory. Notwithstanding the foregoing
provisions of this Section 2.1(b), Auxilium shall not exercise its license pursuant to this Section 2.1(b) to Manufacture the Product except as permitted by, and solely for the purposes set forth in, Article 6. 
 (c) The licenses granted under Sections 2.1(a) and 2.2(b) shall include the right to grant sublicenses (and in the case of Section 2.1(a),
distribution rights); provided, however, that all such sublicenses shall contain terms and conditions which are consistent with the terms and conditions contained in this Agreement. 
 2.2 Option to License Additional Indications 
 (a) Development of Additional Indications for Products. The Parties shall cooperate in good faith in generating ideas and concepts for Additional Indications for Products. BTC shall use Commercially Reasonable Efforts to conduct
Stage I Development for the use of the Product for the treatment of Frozen Shoulder. BTC shall summarize such efforts in reports to be submitted to the Joint Development Committee on a quarterly basis. 
 (b) Option Grant. Subject to the terms and conditions of this Agreement, BTC hereby grants to Auxilium an exclusive option to an exclusive license
to Products in the Territory for each Additional Indication on the same terms and conditions as provided for Indications in the Field (each, an “Additional Indication Option”). 
 (c) Exercise Period; Exercise of Option. The period during which Auxilium may exercise an Additional Indication Option (the “Exercise
Period”) shall commence on the date on which BTC submits a Phase II Clinical Trial report to Auxilium for the Product for such Additional Indication and ends one hundred and twenty (120) days thereafter. BTC shall provide Auxilium with a
copy of a Phase II Clinical Trial report and, any additional data or results in its control. Auxilium may exercise the Additional Indication Option at any time during the Exercise Period by delivering to BTC a written notice of exercise with regard
to such Additional Indication (each, an “Exercised Indication”) that sets forth the effective date of the exercise (the “Exercised Indication Date”). Upon receipt, BTC shall counter-sign the exercise notice which shall then be
appended to and incorporated by reference into this Agreement effective the Exercised Indication Date. 
  

 8 








 (d) License Grant Upon Exercise of Option. Effective on the Exercised Indication Date, the Field
definition shall be amended and expanded to include the relevant Exercised Indication. 
 (e) Auxilium Remaining Indications. Auxilium
shall have the right to Develop and Commercialize Auxilium Remaining Indications at its sole cost and expense. Upon notification to BTC of Auxilium’s intent to Develop and Commercialize an Auxilium Remaining Indication, the Field definition
shall be amended and expanded to include such Auxilium Remaining Indication. 
 2.3 Remaining Indications BTC may offer Third Parties
the right under the Licensed Technology to research, Develop, use Commercialize, market, sell and distribute the Product for any Remaining Indication (the “Remaining Indication Rights”), provided that, prior to executing a definitive
agreement with a Third Party for one or more Remaining Indications, BTC must (a) provide Auxilium with a written summary of the material terms of the proposed agreement (the “Offer Terms”), and (b) grant Auxilium an option,
exercisable for seventy-five (75) days after Auxilium’s receipt of the written summary, to agree to equivalent terms, in which case the Parties shall negotiate in good faith an exclusive license agreement on such terms as promptly as
possible thereafter. In the event that Auxilium does not exercise an option to license a Remaining Indication within such seventy-five (75) day period, the Remaining Indication Rights may be licensed to such Third Party on terms and conditions
no less favorable to BTC than the Offer Terms. 
 2.4 Transfer of BTC Know-How Within forty-five (45) days of the Effective Date,
BTC shall, or shall cause its Affiliates to, transfer to Auxilium all material Product Data relating to Dupuytren’s Disease and Peyronie’s Diseases, including but not limited to preclinical, clinical data, clinical trial protocols, study
data tabulations, reports, the right of cross-reference and permission to use in Auxilium Regulatory Data and regulatory filings, investigator-generated data granted by the owners of such data, etc., in reasonably satisfactory form. Promptly, but in
no event more than thirty (30) days, after the Exercised Indications Date, BTC shall, or shall cause its Affiliates to, transfer to Auxilium all Product Data relating to such Exercised Indication, in reasonably satisfactory form. 
 2.5 Exclusivity During the Term and any extension thereof, and for two years thereafter, neither BTC nor any of its Affiliates shall, except as
otherwise set forth and provided in this Agreement, (a) directly or indirectly develop, manufacture, market, sell, detail or promote any Competing Product or (b) encourage off-label use of a Competing Product that could affect labeled
usage of the Product in the Field. In addition, in the event that BTC markets a BTC Product outside the Field within a country in the Territory where Auxilium is promoting the Product within the Field, BTC shall promote the BTC Product under a
trademark different from the Auxilium Trademark, and will not knowingly market, ship, distribute, promote, sell or otherwise put into circulation the BTC Products within the Field in such country or in any other country within the Territory. In the
event that BTC enters into any agreements with its distributors or wholesalers for the BTC Products in a country in the Territory, it shall include in any and all said agreements appropriate provisions providing, to the extent not prohibited by Law,
that the BTC Products must be distributed and sold solely outside the Field within such country in the Territory. In the event that Auxilium enters into any agreements with its 

  

 9 








 
distributors or wholesalers for the Product in the Field, it shall include in any and all said agreements appropriate provisions providing, to the extent not
prohibited by Law, that the Product must be distributed and sold solely within the Field within such country in the Territory. 
 ARTICLE 3

 PRODUCT DEVELOPMENT 
 3.1 Joint Development Committee 
 (a) Formation. As soon as practicable after the execution of this Agreement, BTC and
Auxilium will establish a Joint Development Committee (the “JDC”) made up of two (2) representatives designated by each Party hereto to assist in coordinating scientific interactions and resolving potential disagreements between BTC
and Auxilium during the course of the Development of Product. The JDC Chair will be appointed by Auxilium from among the members of the committee designated by Auxilium. Each of BTC and Auxilium shall have one vote on the JDC and, in the event of a
deadlock with respect to any action, the vote of Auxilium , rendered after reasonable and open discussion among the members of the JDC, shall be final and controlling. BTC shall not take any action with respect to Remaining Indications that would be
detrimental to the Product or damaging to Auxilium. Notwithstanding the foregoing, BTC will advise the JDC of all Development and Commercialization of Remaining Indications. The JDC shall have the right to discuss and comment on such activities but
shall not have the final vote with respect to such activities as they relate to Remaining Indications. 
 (b) Quarterly Meetings.
While a Product is under Development, the JDC shall meet formally at least quarterly, or with such other frequency, and at such time and location, as may be established by the JDC, for the following purposes, among others: (i) to oversee and
coordinate Development activities of the Parties for Products; (ii) to receive and review reports by the Parties as may be submitted to the JDC on a quarterly basis; and (iii) to discuss matters relating to Patents related to the Product,
including but not limited to issues of inventorship and decisions relating to the filing, prosecution and maintenance of such Patents, provided however, when the JCC is established, the JCC and the JDC will coordinate responsibility on such matters.
Meetings of the JDC may be held in person or by teleconference, as may be determined by the JDC. 
 3.2 Auxilium’s Stage II
Development Activities. 
 (a) Dupuytren’s Disease and Peyronie’s Disease. As soon as it has received the relevant
Product Data pursuant to Section 2.4, Auxilium shall assume all responsibility for (including financial responsibility), and have sole discretion over, all continuing Development of the Product for Dupuytren’s Disease and Peyronie’s
Disease including all Clinical Trials underway as of the Effective Date and listed on Schedule 3.2. Auxilium shall not have financial responsibility for Development Costs or any other costs incurred in connection with Development related to
Dupuytren’s Disease and Peyronie’s Disease prior to the Effective Date. 
  

 10 








 (b) Exercised Indications On each Exercised Indication Date, Auxilium shall be entitled to assume
responsibility for, and have sole discretion over, all continuing Development activities for the Product for each such Exercised Indication. Auxilium shall have one (1) year after the relevant Exercised Indication Date to initiate Stage II
Development for such Exercised Indication, provided, however, that such obligations shall not be binding upon Auxilium to the extent that BTC fails to (i) deliver material Product Data to Auxilium in accordance with Section 2.4, or
(ii) supply Auxilium with material amounts of clinical supplies of the Product for use in the Field in accordance with the delivery scheduled specified by Auxilium under the terms of Section 6.3. 
 (c) Cooperation The Parties agree to cooperate with respect to the transfer of Development activities from BTC to Auxilium including transferring
Clinical Trials and making introductions of Auxilium to clinical investigators and opinion leaders. 
 (d) Stage II Development
Costs. 
 (i) Dupuytren’s Disease and Peyronie’s Disease. Auxilium shall be responsible for all the
Development Costs related to the Product for Dupuytren’s Disease and Peyronie’s Disease and incurred by Auxilium after the Effective Date; provided, however, that BTC shall continue to be responsible for all Development Costs which are
which are incurred prior to the Effective Date. 
 (ii) Exercised Indications. In the event Auxilium assumes
responsibility for Stage II Development of the Product for an Exercised Indication, Auxilium shall be responsible for all Development Costs related to the Product for such Exercised Indication and incurred by Auxilium after the Exercised Indication
Date; provided, however, that BTC shall continue to be responsible for all Development Costs which are incurred prior to the Exercised Indication Date. 
 (iii) Right of Set-Off. To the extent that Auxilium pays any Stage I Development Costs resulting from additional Stage I Development that is requested or required by a Regulatory Authority after assuming
responsibility for Development of the Product for any Indication, Auxilium shall be entitled to set-off the amount of such Stage I Development Costs against any amounts due to BTC pursuant to Section 7.1. 
 3.3 Data and Records 
 (a)
Ownership of Data. Auxilium shall retain ownership of all Product Data, information and results related to Development activities for the Product, provided, however, that Auxilium hereby grants to BTC a right of reference with respect to
Remaining Indications to the Regulatory Data contained in Regulatory Approvals Controlled by Auxilium for the Product in the Field. Notwithstanding the foregoing, (a) if Auxilium’s license rights to the Product terminate with
respect to an Indication within the Field, Auxilium shall assign BTC its right, title and interest in and to the Product and Regulatory Data for that Indication, and (b) if Auxilium’s license rights to a Product hereunder terminate
entirely, Auxilium shall assign BTC its right, title and interest in and to all such Product and Regulatory Data; provided, however, that Auxilium may maintain a copy of such Regulatory Data for legal and archival purposes. 
  

 11 








 (b) Development Records. Each Party shall each maintain records in sufficient detail and in good
scientific manner appropriate for patent purposes and as will properly reflect all work done and results achieved in the performance of Development activities hereunder (including all Regulatory Data in the form required to be maintained under any
applicable governmental regulations). Such records shall include books, records, reports, research notes, charts, graphs, comments, computations, analyses, recordings, photographs, computer programs and documentation thereof, computer information
storage means, samples of materials and other graphic or written data generated in connection with the Development activities. Subject to the terms and conditions of Article 10 below, each Party shall provide the other the right to inspect (no more
than once a year) such records upon reasonable request and during normal business hours, and shall provide copies of all requested records, to the extent reasonably required for the performance of the requesting Party’s obligations under this
Agreement. 
 ARTICLE 4 
 REGULATORY MATTERS 
 4.1 Efforts Within twelve (12) months of filing for Regulatory Approval in any Major Market
Country, Auxilium will file for Regulatory Approval in all the Major Market Countries. Notwithstanding the foregoing, if a different dossier is required for any such other Major Market Country(ies), Auxilium will exercise Commercially Reasonable
Efforts to seek Regulatory Approval with respect to such country(ies). Auxilium may develop additional formulations, dosage forms or delivery systems for the Product in the Field as may be commercially practicable at its own expense. For purposes of
clarity, Remaining Indications shall not be subject to this Article 4; provided, however, that BTC shall not conduct Development or Commercialization of Product in such Remaining Indication in a manner that jeopardizes Auxilium’s Development or
Commercialization of Product in the Field. 
 4.2 Regulatory Matters in the Territory. As between the Parties, Auxilium shall be
responsible in the Territory for ensuring compliance with all regulatory requirements relating to the Product labeled for use in the Field (i.e., obtaining, maintaining, and updating all required any Regulatory Approvals). Without limiting the
foregoing, Auxilium shall (i) file all regulatory filings and supporting documentation; (ii) serve as the designated regulatory official for purposes of receiving communications from the Regulatory Authority; and (iii) report any
Adverse Drug Experience to Regulatory Authorities. 
 4.3 Ownership. All Regulatory Approvals relating to the Products labeled for use
in the Field shall be the property of Auxilium and held in the name of Auxilium or its designee. BTC shall promptly take whatever steps necessary to transition any existing regulatory filings to Auxilium. As promptly as possible after the Effective
Date, BTC shall cause the Investigational New Drug (“IND”) [**] and IND [**], and all foreign counterparts thereof, to be assigned to Auxilium. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED PURSUANT TO AN ORDER GRANTING CONFIDENTIAL TREATMENT ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.


  

 12 








 4.4 Regulatory Interactions for Product. 
 (a) Communications with Regulatory Authority; Advice of Counsel. BTC shall not communicate with Regulatory Authorities, or take any action
regarding an investigation or a request by a Regulatory Authority with respect to a Product in the Field, except (i) with the prior written consent of Auxilium, or (ii) upon the advice of legal counsel that such communication is required
by Law. BTC shall cooperate with Auxilium and provide all reasonable assistance and take all actions reasonably requested by Auxilium that are necessary to comply with any Law applicable to a Product in the Field. If BTC is advised by its legal
counsel that it must communicate with any Regulatory Authority, then BTC shall promptly, but in no event more than two (2) Business Days, advise Auxilium of the same and provide Auxilium in advance with a copy of any proposed written
communication with such Regulatory Authority and comply with any and all reasonable requests of Auxilium concerning any such communication with such Regulatory Authority. 
 (b) Receipt of Correspondence; Inspections. Each Party shall promptly, but in any event within three (3) Business Days, (i) provide to the other copies of any material documents or correspondence
received from any Regulatory Authority related to Development activities for a Product and (ii) inform the other Party of any inspections, proposed regulatory actions, investigations or requests for information or a meeting by any Regulatory
Authority with respect to a Product. In the event BTC does not have advance notice of an inspection by a Regulatory Authority, it shall immediately notify Auxilium of such inspection and it shall cooperate with such Regulatory Authority. 

(c) Recalls and Withdrawals. Subject to the terms and conditions of the Supply Agreement, Auxilium shall have sole responsibility for and shall
make all decisions with respect to any recall, market withdrawals or any other corrective action related to the Products labeled for use in the Field in the Territory; provided however, (i) Auxilium shall immediately notify BTC of any decision
to initiate a recall or withdrawal of such Product; (ii) all costs and expenses with respect to a recall, market withdrawal or other corrective action for such Product shall be borne by Auxilium unless such recall, market withdrawal or other
corrective action was due to the negligence, willful misconduct or material breach of this Agreement or the Supply Agreement by BTC; and (iii) BTC shall immediately notify Auxilium of any decision to initiate a recall or withdrawal of a Product
outside of the Field. Each Party shall provide the other Party with recall information received by it in sufficient detail to allow the Parties to comply with Law. 
 (d) Notice. Each Party shall provide the other Party with notice, in a sufficiently timely basis to enable the other Party to comply in all material respects with Laws, of notification or other information
which it receives (directly or indirectly) from, any Regulatory Authority (and providing, as soon as reasonably possible, copies of any associated written requests) that (i) raises any material concerns regarding the safety or efficacy of a
Product; (ii) indicates or suggests a claim of a Third Party arising in connection with a Product, or (iii) is reasonably likely to lead to a recall or market withdrawal of a Product, provided that neither Party shall be obliged to
disclose information in breach of any contractual restriction which it could not reasonably have avoided or which disclosure would waive any legal privilege. 
  

 13 








 4.5 Inquiries, Adverse Events, etc. As between the Parties, Auxilium shall be responsible for the
surveillance, receipt and evaluation of product complaints for Product labeled for use in the Field in the Territory and reporting to Regulatory Authorities Adverse Drug Experiences for the Products in the Field. As between the Parties, BTC shall be
responsible for the surveillance, receipt and evaluation of product complaints for Product labeled for use outside the Field and reporting to Regulatory Authorities Adverse Drug Experiences for the Products outside the Field. Each Party shall ensure
that, in the Development or Commercialization of the Product, it will record, investigate, summarize, notify, report and review all Adverse Drug Experiences in accordance with Law. Each Party shall (i) adhere to all requirements of Laws which
relate to the reporting and investigation of Adverse Drug Experiences, and (ii) keep the Parties informed of such events. 
 (a) Each
Party shall submit reports of all Adverse Drug Experiences associated with the use of the Product and other required safety information (e.g., PSUR’s or annual safety reports) to the Regulatory Authorities in accordance with Law. Each Party
shall submit a copy of each such report to the other Party in advance of such submission to permit the other Party to comply with legal requirements applicable to it and comment on such reports. 
 (b) Each Party shall submit reports of all Adverse Drug Experiences associated with the use of Product for which Regulatory Approval has not been
achieved and other required safety information to the Regulatory Authorities in accordance with Law. Each Party shall submit a copy of each such report to the other Party in advance of such submission to permit the other Party to comply with legal
requirements applicable to it and comment on such reports. 
 (c) In order to accomplish the objectives of this Section and to the extent
required by Law, within one hundred and eighty (180) days of the Effective Date, the Parties shall discuss and develop an agreement containing mutually acceptable guidelines and procedures for the receipt, recordation, communication, exchange
and reporting of Adverse Drug Experiences for the Product. 
 4.6 Approval of Labeling and Promotional Materials. Auxilium shall be
responsible to seek or obtain any necessary Regulatory Authority approvals of any label, labeling, package inserts or outserts, monographs and packaging, and promotional materials for use in connection with the Products labeled for use in the Field
and for determining whether the same requires approval from Regulatory Authority. The Parties shall cooperate in such efforts to seek and obtain such approvals. 
 4.7 Cooperation. The Parties shall cooperate to provide each other all reasonable assistance and take all actions reasonably requested that are necessary to comply with Laws, including safety updates,
amendments, annual reports, pharmacovigilance filings, investigator notifications, facility inspections, and certifications and maintenance and updates for regulatory filings and Regulatory Approvals. Unless otherwise provided under the terms of
this Agreement, the Parties will cooperate, communicate and provide reasonable assistance to each other with regard to all CMC matters related to the Product. 
  

 14 








 ARTICLE 5 
 COMMERCIALIZATION 
 5.1 Joint Commercialization Committee. 
 (a) Formation. Not later than the commencement of Phase III Clinical Trials for any Product, BTC and Auxilium will establish a Joint
Commercialization Committee (the “JCC”) made up of two (2) representatives designated by each Party hereto to assist in coordinating interactions and resolving potential disagreements between BTC and Auxilium during the course of the
Commercialization of Product. The JCC shall meet each and every calendar quarter. The JCC Chair will be appointed by Auxilium from among the members of the committee designated by Auxilium. Auxilium and BTC shall each have one vote on the JCC. The
objective of the JCC shall be to reach agreement by consensus on all matters falling within its authority hereunder. In the event of a deadlock with respect to any action, the vote of Auxilium, after reasonable opportunity for open discussion among
the members of the JCC, shall control. Notwithstanding the foregoing, the JCC shall not have authority to commit the financial resources of either party. 
 (b) Patent Position. The JCC will coordinate with the JDC in discuss matters relating to Patents related to the Product, including but not limited to issues of inventorship and decisions relating to the filing,
prosecution and maintenance of such Patents. 
 (c) Coordinated Strategy. The JCC shall meet at least quarterly or with such frequency
and at such time and location as may be established by the JCC and will monitor the overall strategy and oversee the global marketing of all Products. The JCC will have the opportunity to review market research plans and research results, clinical
development results and similar items for each Product, including Products Developed for Remaining Indications, for the purpose of advising and assisting in communicating a unified global marketing strategy; provided, however, that with respect to
Remaining Indications, the JCC shall not have the final vote. 
 5.2 Commercialization. Auxilium shall use Commercially Reasonable
Efforts to Commercialize the Product in the Field in each country in the Territory. Subject to Section 5.4 below, Auxilium shall be responsible for and have sole discretion over all aspects of Commercialization of the Product for use in the
Field in the Territory. 
 5.3 Orders, Booking Sales. Auxilium shall have the sole right and responsibility for Product in the Field
in each country in the Territory to (a) receive, accept, and fill orders for such Product, (b) control invoicing, order processing, and collection of accounts receivable for such Product sales, and (c) record such Product sales in its
books of account. If, for any reason, BTC receives orders for such Product, BTC shall forward such orders to Auxilium (or, if directed by Auxilium, to Auxilium’ wholesalers) as soon as practicable. If any quantities of such Product are returned
to BTC, BTC shall immediately notify Auxilium and ship them to the facility designated by Auxilium. 
  

 15 








 5.4 BTC Co-Promotion Rights. In the event that BTC provides written notice of its intent within
ninety (90) days after an NDA Acceptance for a Product in the Field in the Territory indicated for use for any Exercised Indication, BTC will be allowed to provide up to ten percent (10%) of the Product Details for such Indication. In
addition, in the event that BTC provides written notice of its intent within ninety (90) days after an NDA Acceptance for Frozen Shoulder, BTC will be allowed to provide up to ten percent (10%) of the Product Details for Dupuytren’s
Disease. Notwithstanding Section 13.10, BTC’s co-promotion rights granted pursuant to this Section shall not be assignable or transferable to any other Person. 
 ARTICLE 6 
 MANUFACTURE AND SUPPLY 
 6.1 Joint Manufacturing Committee. 
 (a) Within forty-five (45) days after the Effective Date, BTC and Auxilium will establish a Joint Manufacturing Committee (the “JMC”) made up of two (2) representatives designated by each Party hereto to which shall
oversee the manufacturing of Product on a worldwide basis, including the planning, manufacturing and supply (including supply chain management). The JMC Chair will be appointed by BTC from among the members of the committee designated by BTC. Each
of BTC and Auxilium shall have one vote on the JMC. The objective of the JMC shall be to reach agreement by consensus on all matters falling within its authority hereunder. In the event of a deadlock with respect to any action, the vote of BTC,
after reasonable opportunity for open discussion among the members of the JMC, shall control. 
 (b) Specific Responsibilities of the
JMC. In support of its responsibility for overseeing the Manufacturing of Product on a worldwide basis the JMC shall meet at least quarterly or with such higher frequency, and at such time and location as may be established by the JMC, and the
JMC shall perform the following activities: 
 (i) delineate requirements and responsibilities for development and licensure
of manufacturing processes and facilities for Product and for supply of Product in the Territory; 
 (ii) together with the
Joint Development Committee, develop a manufacturing strategy to enable development and licensure of manufacturing processes and facilities for Product in the Territory that includes all aspects of manufacture and release, including but not limited
to formulations, intermediate, dosage form, devices, product characterization studies, stability studies and manufacturing plans and forecasts; 
 (iii) review quality assurance efforts, including but not limited to those efforts with respect to the establishment of specifications and quality standards for Product; 
 (iv) together with the Joint Development Committee review and comment on the process for Product Development and the drafting and contents
of the CMC section of a Drug Approval Application for Product; 
  

 16 








 (v) review technology transfer plans for any changes in manufacturing sites, testing
sites, and responsibilities in the supply chain for Product, it being understood that decisions regarding the selection of which of a Party’s own manufacturing and testing sites shall be used to manufacture any component of a Product, if a
Party manufactures any component of a Product pursuant to this Agreement or any related supply agreement, shall remain in the sole control of such Party; 
 (vi) prepare for regulatory inspections and ensure adherence to compliance standards with respect to Product; and 
 (vii) review quality compliance and manufacturing related regulatory issues concerning the Product or any component thereof as important issues arise through meetings and review of relevant written material produced
by Auxilium, BTC or any Regulatory Authority. 
 6.2 Development and Scale-Up. BTC shall, at its own cost and expense, develop the
formulation and the finished dosage form and scale-up the Manufacture for commercial supply of the Enzyme and the Product for each Indication for use in the Field, including the [**], to be registered with Regulatory Authorities in accordance
with Law and in sufficient time prior to anticipated commercial launch of a Product to provide for sufficient supply of Product for use in the Field. Notwithstanding the foregoing, Auxilium will have the sole right and responsibility for selecting
the finished dosage form and presentation for the Product in the Field. 
 6.3 Clinical Supply. 
 (a) Supply by BTC. BTC shall be responsible for supplying or arranging for the supply of the Product suitable for use by Auxilium in Clinical
Trials. All the Product shall be Manufactured in accordance with applicable specifications, all Laws, and shall be subject to the Standard Terms set forth in below. BTC will supply Auxilium, free of charge, with bulk vials containing sufficient
quantities of the Product to treat up to five hundred [**] patients per year in Clinical Trials. If Auxilium requires additional clinical supplies, BTC will supply Auxilium with such clinical supplies at its Cost of Goods. Auxilium will be
entitled to qualify a back up supplier for the Manufacture of clinical and commercial supplies of Product in the Field (the “Back-Up Supplier”) at any time after the Effective Date. BTC will use Commercially Reasonable Efforts to
ensure that such Back-Up Supplier has sufficient know-how to Manufacture Product, including (i) providing all protocols, registration applications and other substantive regulatory documents, including, but not limited to, all data, scientific
dossiers and governmental authorizations; (ii) providing access and reference to all regulatory dossiers and filings produced by BTC, its Affiliates and sublicensees relating to the Product; (iii) providing access to BTC Know-How in
reasonably satisfactory form, and (iv) providing all technical assistance reasonably requested by the Back-Up Supplier related to the Manufacture of the Product. Auxilium will require that the Back-up Supplier execute a written confidentiality
agreement with both Auxilium and BTC, in a form consistent with industry standards, which includes, among 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED PURSUANT TO AN ORDER GRANTING CONFIDENTIAL TREATMENT ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.


  

 17 








 other things, an undertaking by the Back-up Supplier to keep confidential the manufacturing information and know-how
disclosed to the Back-up Supplier by BTC. In the manufacturing information and know-how disclosed to the Back-up Supplier by BTC. In addition, Auxilium will use reasonable commercial efforts to seek the cooperation of the Back-up Supplier in sharing
with BTC and Auxilium information concerning the Manufacture of the Product that Back-up Supplier may acquire in connection with such Manufacture. 
 (b) Notification of Requirements. Auxilium will provide BTC with one hundred and eighty (180) days notice of its requirements for clinical supplies of Product including a delivery schedule and address. BTC will provide notice
within three (3) Business Days of receipt of such notice if BTC is unable to supply Auxilium with the quantities of clinical supplies of Product in accordance with the delivery schedule. In such event, the Parties shall cooperate but BTC shall
be primarily responsible, at its sole cost and expense, for procuring such quantities of Product from the Back-Up Supplier as are necessary to compensate for any such deficiency. 
 (c) Late Delivery of Clinical Supply. In the event that BTC is more than thirty (30) days late in delivering such material amount of clinical
supplies, in addition to any other remedies Auxilium may have in Law or equity, BTC will forgive Auxilium seven thousand five hundred dollars ($7500) per day for each additional day, such amounts to be creditable against any milestone payments due
to BTC under Article 7. 
 6.4 Commercial Supply; Supply Agreement. BTC will supply or arrange for the supply of all necessary
commercial quantities of the Product in the Territory. No later than three (3) months after the Effective Date, the Parties shall enter into a commercial supply agreement on customary and reasonable terms and conditions (the “Supply
Agreement”), such Supply Agreement shall include the following: 
 (a) Royalty. Auxilium will pay BTC on a country-by-country
and Product by Product basis a royalty payment of six percent [**] of Net Sales of Products in the Field for the Term. Such royalty may be reduced as follows: 
 (i) Competing Product Sales. If a Competing Product is sold in a country in the Territory with a unit based market share of
[**]% or greater, then there shall be no royalty due for sales in that country in the Territory. 
 (ii) Third Party
Royalties. If the Manufacturing, Development or Commercialization of the Product by the Parties in accordance with this Agreement would, but for a license from such Third Party, infringe on such Third Party Patents, any royalties or other
payments due to Third Parties pursuant to a license acquired by Auxilium then the royalty may be reduced by up to [**]% by such the royalty amounts to a floor of not less than three percent [**]% in any case. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED PURSUANT TO AN ORDER GRANTING CONFIDENTIAL TREATMENT ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.


  

 18 








 (b) Supply Price. 
 (i) Basic Supply Price. Subject to the adjustments set forth below, the “Supply Price” for the Product shall be
calculated as a percentage of Net Sales as follows: 
  

					
	 Annual Sales Volume (# Vials)
	 	 	  	 Supply Price (as % of Net Sales)

	 [**]
	 		  	[**]%
	 [**]
	 		  	[**]%
	 [**]
	 		  	[**]%
	 [**]
	 		  	[**]%
	 [**]
	 		  	[**]%

 Provided, however, the Supply Price shall not equal less than [**]% of BTC’s Cost of
Goods for the Product as provided in Schedule 1.16 (the “Minimum Supply Price”). 
 (ii) Adjustments to Supply
Price. 
 (A) Most Favored Customer. Notwithstanding anything in this Agreement to the contrary, if at any time
during the Term BTC sells or provides products including Enzyme as an active ingredient to any customer for commercial use at rates more favorable than those accorded to Auxilium, BTC shall promptly offer Auxilium the benefit of such more favorable
terms and conditions or rates, which, upon acceptance, shall be retroactive to the date that such more favorable terms and conditions were first effective for such other customer. In order for Auxilium to receive more favorable cost rates, Auxilum
must accept the same basic business deal conditions as those provided to a party receiving the more favorable rates. Upon Auxilium’s reasonable request, BTC shall provide written confirmation that it is in compliance with the requirements of
this Section. 
 (B) Reduction In Cost of Goods. If BTC is successful in reducing the Cost of Goods, the Supply Price
to Auxilium will be reduced by [**]% of such dollar reduction. 
 (C) Supply of Samples. Product samples shall
be provided at no charge to Auxilium for use in post-market clinical trials and for selected use as commercial samples for dispensing to patients by an appropriate health care provider, but in no event for direct distribution to patients. The number
of Product samples to be provided to Auxilium shall be set forth in the Supply Agreement. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED PURSUANT TO AN ORDER GRANTING CONFIDENTIAL TREATMENT ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.


  

 19 








 (D) Delay in Delivery. If, for any reason other than a force majeure, the BTC
delivers any shipment of Product in accordance with this Article later than the date of delivery set out in the purchase order as agreed by the Parties pursuant to the Supply Agreement then: 
 (1) a 5% reduction in the Supply Price of Product if the shipment is delivered more than thirty (30) days but less than sixty (60) days late;

 (2) a 10% reduction in the Supply Price of Product if the shipment is delivered more than sixty (60) days but less than ninety
(90) days late; and 
 (3) a 15% reduction in the Supply Price of Product if the shipment is delivered more than ninety (90) days
late. 
 (4) Once the price has been reduced in accordance with this Section, it will not revert to the original price unless and until the
deliveries are no longer delayed. 
 (c) Stand-By Rights; Back Up Supplier. 
 (i) Standby Rights. Auxilium will be entitled to seek from the Back-Up Supplier the greater of (a) 25% its requirements and
(b) that quantity of Product that BTC is unable to provide, for a period of one (1) year following the occurrence of any of the events set forth in (A), (B) or (C) below (the “Standby Rights”). In the event that
Auxilium exercises its Standby Rights, the amount of Product that Auxilium is obligated to source from BTC pursuant to the Supply Agreement shall be reduced by such quantity for such one (1) year period. 
 (A) Failure to Meet Firm Order. If, for any reason, including, without limitation, as a result of a force majeure, BTC is unable to
supply at least 75% of the amount of Product specified under a Firm Order, then Auxilium may exercise its Standby Rights by providing written notice; provided, however, that in the event that BTC is unable to supply the full amount specified in
Auxilium’s Firm Order for two consecutive quarters (regardless of the amount of such material shortfall), Auxilium may exercise its Standby Rights by providing written notice to BTC. In addition, Auxilium shall be permitted to seek supply of
any shortfall (regardless of amount of such shortfall or the number of times BTC has fulfill some or all of an Auxilium Firm Order) from the Back-Up Supplier on a per event basis without specifically invoking its Stand-By Rights. 
 (B) Egregious Delivery Delay. If, for any reason, other than a force majeure, BTC delivers any quantity of any Product more than
ninety (90) days after the date such delivery was due, then Auxilium may exercise its Standby Rights by providing written notice. 
 (C) Nonconforming Product. If any three (3) consecutive shipments contain nonconforming Product and BTC (1) fails to replace any nonconforming Product with conforming Product in a timely manner or
(2) fails 

  

 20 








 
to replace nonconforming Product within fifteen (15) Business Days after a dispute regarding whether any rejected quantity of any Product constitutes
nonconforming Product is decided in Auxilium’s favor, then Auxilium may exercise its Standby Rights by providing written notice. 
 (ii) Offset. Auxilium will be entitled to offset any royalties owed to BTC by the amount represented by the difference between the Back Up Supplier’s supply price and BTC’s supply price. 

(iii) BTC’s Use of the Back Up Supplier. If BTC opts to use the Back Up Supplier to provide Product to Auxilium, then BTC
will either reimburse Auxilium for [**] of the documented costs and expenses Auxilium incurred in qualifying, sourcing and maintaining such Back Up Supplier or [**]. 
 (d) Maintenance of Inventory. The Supply Agreement will require that by the time of Commercialization of the Product, BTC will maintain at least a
six (6) month supply of API Enzyme and such reserve supply of Product as may be set forth in the Supply Agreement. 
 (e) Allocation
of Supply. In the event of a shortage of raw materials necessary to Manufacture the Product, BTC shall allocate ninety percent (90%) of the total available supply of raw materials and Product to Auxilium. 
 (f) Continuous Improvement and Reduction of Cost of Goods. BTC shall use reasonable efforts to continuously improve its performance, and any
Product suppliers’ performance in the supply of the Product, including but not limited to, reducing Cost of Goods, increasing yield, and optimizing delivery timing. 
 (g) Standard Terms of Supply. With respect to the supply of the Product, BTC shall make the following representations, warranties, and covenants (the “Standard Terms”): 
 (i) The Product shall be Manufactured in accordance with all Laws and, at the time of delivery of the Product, such the Product will
comply with the specifications, shall be free from defects in materials and workmanship, shall be fit for the purpose for which it is intended, and shall not be adulterated or misbranded within the meaning of the Act, and shall not constitute an
article which may not, under the Act, be introduced into interstate commerce. BTC provides no other warranties, express or implied, regarding the Product and disclaims all other express or implied warranties, including the implied warranties of
merchantability and fitness for a particular purpose. 
 (ii) The Product sold and shipped shall be Manufactured in accordance
with all Laws in effect at the time and place of Manufacture of the Product, and all waste, including all hazardous waste, generated at the time of Manufacture of the Product shall be disposed of in accordance with all Laws; 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED PURSUANT TO AN ORDER GRANTING CONFIDENTIAL TREATMENT ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.


  

 21 








 (iii) All records as are necessary and appropriate to demonstrate compliance with Laws
shall be maintained by BTC and such Manufacture of the Product shall be performed in a facility maintaining a current drug establishment registration with the FDA as set forth in 21 C.F.R. § 207; 
 (iv) BTC shall ensure that it, its Affiliates, and its subcontractors maintain all Governmental Permits that may be necessary to
Manufacture and ship the Product; 
 (v) BTC shall advise Auxilium of any information which arises out of BTC’s, its
Affiliates, and its subcontractors, as applicable, Manufacturing, relating to the Product, which have adverse regulatory compliance or reporting consequences concerning such the Product; 
 (vi) BTC shall provide to Auxilium any information reasonably requested by Auxilium and shall consult Auxilium before providing any
information to any Regulatory Authority in connection with Manufacture of the Product. BTC shall as promptly as possible, but in no event later than within ten (10) days, advise Auxilium of any requests by any Regulatory Authority for
inspections at the premises of BTC or any of its Affiliates or subcontractors with respect to the Product; 
 (vii) In the
event BTC, its Affiliates, or its subcontractors are inspected by the FDA or any similar or related Regulatory Authority relating to the Product, BTC agrees to notify Auxilium of any such inspection and will use Commercially Reasonable Efforts to
ensure that Auxilium shall have the right to be present during such inspection. BTC shall promptly notify Auxilium of any alleged violations or deficiencies relating to a Manufacturing facility at which the Product are Manufactured, packaged, or
stored, and shall promptly disclose to Auxilium all relevant portions of any notice of observations or potential violations as well as a copy of its response thereto; 
 (viii) Neither BTC, its Affiliates nor subcontractors shall use, in the Manufacture of any the Product, in any capacity the services of
any person, including any firm or individual, debarred or subject to debarment under the Generic Drug Enforcement Act of 1992, amending the Act at 21 U.S.C. § 335a. BTC agrees to notify Auxilium immediately in the event any person providing
services to BTC, its Affiliates, or subcontractors relating to this Agreement is debarred or becomes subject to debarment; and 
 (ix) For the purpose of permitting a quality and compliance audit, BTC, its Affiliates, and subcontractors shall grant to authorized representatives of (or a Third Party hired on behalf of Auxilium who is reasonably acceptable to BTC), in
general not more than once per month, upon reasonable notice, access to areas of each of its plants to the extent permitted by Law. Auxilium shall have the right, subject to any Third Party confidentiality obligations and at its sole expense, to
examine those technical records 

  

 22 








 
made by BTC, its Affiliates or subcontractors that relate to the Manufacture of the Product. 
 (h) Customary Terms. The Supply Agreement shall also include provisions for: forecasting and ordering, inventory maintenance requirements;
packaging obligations; back-up suppliers, compliance with applicable regulatory requirements, Auxilium guidelines, and specifications, and all Laws. 
 ARTICLE 7 
 PAYMENTS 
 7.1 Milestone Payments by Auxilium. 
 (a) Amount of Milestone Payments. 
  

							
	 #
	  	 Milestone
	  	 United States Dollars

	1	  	The Effective Date	  	$[**]
	2	  	The delivery to Auxilium of the Product Data relating to Dupuytren’s Disease and Peyronie’s Disease in accordance with Section 2.4 of this Agreement.	  	$[**]
	3	  	The one (1) year anniversary of the Effective Date	  	$[**]	  	
	4	  	Upon first of either NDA Acceptance or MAA Acceptance for the following Indications on an Indication by Indication basis:	  	 Dupuytren’s
 Disease
	  	 $[**]

		  	  	 Peyronie’s
 Disease
	  	$[**]
	5	  	Receipt by Auxilium or its Affiliate of first Regulatory Approval in the United States or three or more of the United Kingdom, Spain, Germany, France or Italy with labeling approved
for the following Indications on an Indication by Indication basis:	  	 Dupuytren’s
 Disease
	  	$[**]
		  	  	 Peyronie’s
 Disease
	  	$[**]

 (b) Timing of Milestone Payments. For milestones 1, 2 and 3, payment shall be made within
ten (10) Business Days after the occurrence of the event giving rise to a payment obligation hereunder. For milestones 4 and 5, payment shall be made within thirty (30) days after the occurrence of the event giving rise to a payment
obligation hereunder. All payments shall be made by wire transfer in United States Dollars to the credit of such bank account as may be designated, from time to time, by BTC in writing. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED PURSUANT TO AN ORDER GRANTING CONFIDENTIAL TREATMENT ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.


  

 23 








 7.2 Process Development Milestones Within thirty (30) days following the Effective Date, BTC
will provide Auxilium with a plan for the scale-up of Manufacturing for clinical and commercial supplies of Product (the “Manufacturing Plan”) which is acceptable to Auxilium. The Manufacturing Plan shall contain, among other things, a
schedule setting forth a timeline for the achievement of certain manufacturing process development milestones (the “Process Development Milestones”). Auxilium shall pay to BTC the amount of $[**] monthly upon achieving the Process
Development Milestones (the “Process Development Payments”); provided, however, that Auxilium may suspend the Process Development Payments at anytime if it determines, in its reasonable judgement that BTC has not consistently met the
Process Development Milestones. For purposes of clarification, in no event will the Process Development Payments exceed $[**] in the aggregate. 
 7.3 Payments for Exercised Indications. 
 (a) Upon Exercise of Option. Within ten
(10) Business Days of the inclusion on Exercised Indications in the Field, Auxilium shall make the following one-time license fee payments to BTC on a per Indication basis: 
  

			
	 Amount
	  	 Indication

	$1,000,000	  	Cellulite reduction
	$   500,000	  	Frozen Shoulder
	$   500,000	  	Each Additional Indication

 (b) Upon Approval. Within ten (10) Business days of receipt by Auxilium of the first
Regulatory Approval from the FDA for an Exercised Indication, Auxilium shall make the following milestone payments to BTC on a per Indication basis: 
  

			
	 Amount
	  	 Labeling Approved for the following Indication

		
	$[**]	  	[**]
		
	$[**]	  	[**]
		
	$[**]	  	[**]
		
	$[**]	  	[**]
		
	$[**]	  	Each Additional Indication

 7.4 Payments Related to Sublicense Income. Within thirty (30) Business Days of
receiving Sublicense Income, Auxilium shall make a payment to BTC in the following amount: 
 7.4.1 If Auxilium has not conducted a Clinical
Trial for Product in the relevant Indication prior to the effective date of the relevant sublicense, then Auxilium will remit [**]% of the Sublicense Income actually received. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED PURSUANT TO AN ORDER GRANTING CONFIDENTIAL TREATMENT ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.


  

 24 








 7.4.2 If Auxilium has conducted Clinical Trials for a Product in the relevant Indication prior to the
date of the relevant sublicense, then Auxilium will remit [**]% of Sublicense Income actually received. 
 7.4.3 Auxilium has obtained
Regulatory Approval for a Product in the relevant Indication prior to the date of the relevant sublicense, then Auxilium will remit [**]% of Sublicense Income actually received. 
 7.4.4 If the field of use of the sublicense to the Product is non-human use, then Auxilium will remit [**]% of the Sublicense Income actually
received for that field of use. 
 7.5 Currency. All payments shall be payable in United States Dollars. 
 7.6 Books and Records. Auxilium agrees to maintain and retain, in accordance with generally accepted accounting practices, complete and accurate
records showing all transactions and information relating to this Agreement for a period of three (3) years from the date of entry to which they pertain. 
 7.7 Audit Rights. Upon the written request of BTC and not more than once in each calendar year, Auxilium shall permit an independent certified public accounting firm (other than on a contingency fee basis)
selected by BTC and acceptable to Auxilium (which acceptance by Auxilium shall not be unreasonably withheld) to have access during normal business hours to such records of Auxilium as may be reasonably necessary to verify Auxilium’s compliance
with the payment terms of this Article 7. The accounting firm shall enter into an acceptable and customary confidentiality agreement with Auxilium obligating the accounting firm to retain in confidence all information of Auxilium which it obtains in
performing such audits hereunder, and such audit shall be subject to Auxilium’s third Party confidentiality obligations. Any audit under this Section 7.7 shall be at the expense of BTC, unless a particular audit reveals an underpayment of
five percent (5%) or more of the amount that should have been paid to BTC for the period audited, in which case, Auxilium shall bear the expense of such audit. 
 7.8 Taxes. Auxilium shall be entitled to deduct from its payments to BTC the amount of any withholding taxes required to be withheld by Auxilium or its Affiliates or sublicensees to the extent BTC or
sublicensees pay to the appropriate governmental authority on behalf of BTC such taxes. Auxilium shall deliver to BTC, upon BTC’s request, proof of payment of all such taxes. Each Party shall provide assistance to the other Party in seeking any
benefits available to such Party with respect to government tax withholdings by any relevant law or double tax treaty. 
 7.9
Interest. Any payments payable by either party which are not paid on or before the date such payments are due under this Agreement (other than such payments which are the subject of a good faith dispute between the Parties) shall bear
interest at the prime rate of interest plus 1%, calculated on the number of days that payment is delinquent. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED PURSUANT TO AN ORDER GRANTING CONFIDENTIAL TREATMENT ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.


  

 25 








 7.10 Blocked Payments. In the event that, by reason of Laws or regulations in any country, it
becomes impossible or illegal for Auxilium or an Affiliate or sublicensee of Auxilium, to transfer, or have transferred on its behalf, distribution fees or other payments to BTC, Auxilium shall promptly notify BTC of the conditions preventing such
transfer and such distribution fees or other payments shall be deposited in local currency in the relevant country to the credit of BTC in a recognized banking institution designated by BTC or, if none is designated by BTC within a period of thirty
(30) days, in a recognized banking institution selected by Auxilium or its Affiliate or sublicensee, as the case may be, and identified in a notice given to BTC. 
 ARTICLE 8 
 INTELLECTUAL PROPERTY 
 8.1 BTC Patentable Inventions and Know-How. 
 (a) BTC Patent Prosecution. 
 (i) During the term of the Agreement, BTC shall, diligently and in the
reasonable exercise of its commercial discretion, prepare, file, prosecute, maintain, renew and defend BTC Patents in the countries where such BTC Patents are filed as of the Effective Date; provided, however, that BTC shall select patent counsel
with Auxilium’s consent, such consent not to be unreasonably withheld. 
 (ii) If BTC does not intend to file for patent
protection or does not wish to continue preparation, prosecution, or maintenance of a BTC Patent, then it shall give at least thirty (30) days advance notice, and in no event less than a reasonable period of time for Auxilium to act in its
stead. 
 (A) In such case, Auxilium may elect at its sole discretion to continue preparation, filing and prosecution or
maintenance of the discontinued BTC Patent at its sole expense. 
 (B) Ownership of any such discontinued BTC Patent shall at
the request of Auxilium be assigned to Auxilium and BTC shall execute such documents and perform such acts as may be reasonably necessary for assigning such ownership to Auxilium. 
 (C) Discontinuance may be elected on a country-by-country basis or for a patent application or patent series in total. 
 (b) Cooperation. BTC will consult Auxilium and will keep Auxilium continuously informed of all matters relating to the filing, prosecution and
maintenance of BTC Patents including, but not limited to, disclosing to Auxilium the complete text of all such BTC Patents. 
 (i) BTC shall provide Auxilium with a copy of any BTC Patents relating to Enzyme or Product withing thirty (30) days of the Effective Date. Prior to filing the first of any new Patents in any jurisdiction, BTC shall provide Auxilium
with a 

  

 26 








 
copy of any such Patent applications and copies of all material correspondence with the relevant patent office pertaining to the BTC Patents and directly
relating to Enzyme or Product. 
 (ii) BTC shall consider all of Auxilium’s comments in good faith and take all steps
reasonably necessary to optimize the patent position for the Product. 
 (iii) In no event shall BTC relinquish control of the
prosecution of BTC Patents to a Third Party. 
 8.2 Infringement Claims by Third Parties. 
 (a) Notice. If the manufacture, use or sale of the Product under the BTC Patents results in a claim or a threatened claim by a Third Party against
a Party hereto for patent infringement or for inducing or contributing to patent infringement (“Infringement Claim”), the Party first having notice of an Infringement Claim shall promptly notify the other in writing. The notice
shall set forth the facts of the Infringement Claim in reasonable detail. 
 (b) Third Party Licenses. In the event that practicing
under the BTC Patents in connection with manufacture, use or sale of the Product in a country would infringe a Third Party Patent and a license to such Third Party Patent is available and Auxilium in its sole discretion seeks such a license, the
Parties agree: 
 (i) Auxilium will be responsible for all costs associated with acquiring any Third Party license to the
extent required for Auxilium to continue to make, use and sell the Product and the Enzyme, provided however, Auxilium may offset such costs against the Royalty, with a minimum floor of [**]% in accordance with Section 6.4 or, prior to
commercial launch, offset such costs against any milestones due to BTC pursuant to Article 7; and 
 (ii) Auxilium will use
Commercially Reasonable Efforts to obtain any such required licenses under the Third Party’s Patents with a right to sublicense to BTC and if requested by BTC will grant such sublicense, under reasonable sublicense terms mutually acceptable to
both BTC and Auxilium. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED PURSUANT TO AN ORDER GRANTING CONFIDENTIAL TREATMENT ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.


  

 27 








 (c) Litigation. In the event of the institution of any suit by a Third Party against Auxilium as a
result of Auxilium’s Development or Commercialization of the Product or the Enzyme, Auxilium shall have the right but, not the obligation, to defend such suit at its expense; BTC shall cooperate and assist Auxilium in any such litigation at
Auxilium’ expense. In the event of the institution of any suit by a Third Party against BTC as a result of BTC’s Manufacture of the Product or the Enzyme, BTC shall have the right but, not the obligation, to defend such suit at its
expense. Auxilium shall cooperate and assist BTC in any such litigation at BTC’s expense. For purposes of clarity, notwithstanding anything to the contrary in Article 12, to the extent applicable, Auxilium will be entitled to seek
indemnification from BTC for Losses arising in connection with such suit. 
 8.3 Infringement Claims Against Third Parties.

 (a) Cooperation. BTC and Auxilium each agree to take reasonable actions to protect BTC Patents from infringement. If one Party
brings any such action or proceeding, the second Party may be joined as a Party plaintiff if necessary for the action or proceeding to proceed and, in case of joining, the second Party agrees to give the first Party reasonable assistance and
authority to file and to prosecute such suit. 
 (b) Notice. If any BTC Patents are infringed by a Third Party, the Party to this
Agreement first having knowledge of such infringement, or knowledge of a reasonable probability of such infringement, shall promptly notify the other in writing. The notice shall set forth the facts of such infringement in reasonable detail.

 (c) Institution of Proceedings. BTC, shall have the primary right, but not the obligation, to institute, prosecute, and control
with its own counsel at its own expense any action or proceeding with respect to infringement of the claims of such BTC Patents and Auxilium shall have the right, but not the obligation at its own expense, to be represented in such action by its own
counsel. 
 (d) Failure to Institute Proceedings. If BTC fails to institute, prosecute, and control such action or prosecution and
fails to do so within a period of one hundred twenty (120) days after receiving notice of the infringement, Auxilium shall have the right to bring and control any such action by counsel of its own choice, and BTC shall have the right, at its
own expense, to be represented in any such action by counsel of its own choice. 
 (e) Division of Damages Award. Any recovery made in
connection with such infringement claim shall be divided as follows: 
 (i) the Party that initiated and prosecuted such
action shall recoup all of its costs and expenses (including reasonable attorney’s fees) incurred in connection with such action, whether the recovery is by settlement or otherwise; 
 (ii) the other Party then shall, to the extent possible, recover its costs and expenses (including reasonable attorney’s fees)
incurred in connection with such action; 
  

 28 








 (iii) if BTC initiated and prosecuted the action, the amount of any recovery remaining
shall be retained by BTC; and 
 (iv) if Auxilium initiated and prosecuted the action, the amount of any recovery remaining
shall be retained by Auxilium, except that BTC shall receive a portion equivalent to the amount it would have received in accordance with the terms of Section 6.4 as if such amount were Net Sales of Auxilium. 
 (f) Settlement. The Parties shall keep each other informed of the status of and of their respective activities regarding any litigation or
settlement thereof concerning Product; provided, however, that no settlement or consent judgment or other voluntary final disposition of a suit under this Section may be undertaken without the consent of the other Party if such settlement would
require the other Party to be subject to an injunction or to make a monetary payment or would otherwise adversely affect the other Party’s rights under this Agreement or the validity of BTC Patents. 
 8.4 Notice of Certification. BTC and Auxilium each shall immediately give notice to the other of any certification filed under the “U.S. Drug
Price Competition and Patent Term Restoration Act of 1984” (or its foreign equivalent) claiming that a BTC Patent is invalid or that infringement will not arise from the manufacture, use or sale of any Product by a Third Party. 
 (a) If BTC decides not to bring infringement proceedings against the entity making such a certification, BTC shall give notice to Auxilium of its decision
not to bring suit within twenty one (21) days after receipt of notice of such certification. 
 (b) Auxilium may then, but is not
required to, bring suit against the Party that filed the certification; provided, however, that the costs incurred by Auxilium in connection with such suit shall be creditable against milestone payments payable by Auxilium in accordance with Article
7. 
 (c) Any suit by Auxilium or BTC shall either be in the name of Auxilium or in the name of BTC, or jointly in the name of Auxilium and
BTC, as may be required by law. 
 (d) For this purpose, the Party not bringing suit shall execute such legal papers necessary for the
prosecution of such suit as may be reasonably requested by the Party bringing suit. 
 8.5 Patent Term Extensions. The Parties shall
cooperate in good faith with each other in gaining patent term extension wherever applicable to BTC Patents covering Enzyme or Product. 
 (a)
Auxilium and BTC shall jointly determine which BTC Patents shall be extended. 
 (b) All filings for such extension shall be made by the
Party responsible for prosecution and maintenance of the BTC Patent, provided, however, that in the event that the Party who is responsible for prosecution and maintenance of the BTC Patent elects not to file for 

  

 29 








 
an extension, such Party shall (i) inform the other Party of its intention not to file and (ii) grant the other Party the right to file for such
extension. 
 8.6 Trademarks. 
 (a) Each Party and its Affiliates shall retain all right, title and interest in and to its and their respective corporate names and logos. 
 (b) Auxilium shall be solely responsible for selecting a trademark (the “Auxilium Trademark”) to use for each country in the Territory. The Product shall be promoted and sold, in accordance with the provisions of this Agreement,
in the Territory under the Auxilium Trademark. Auxilium (or its local Affiliates, as appropriate) shall own and retain all rights to Auxilium Trademark, and all goodwill associated therewith throughout the Territory. Auxilium shall also own rights
to any internet domain names incorporating the Auxilium Trademark or any variation or part of Auxilium Trademark as its URL address or any part of such address. 
 ARTICLE 9 
 REPRESENTATIONS AND WARRANTIES 
 9.1 BTC Represents and Warrants. BTC hereby represents and warrants to Auxilium that: 
 (a) This Agreement has been duly executed and delivered by BTC and constitutes the valid and binding obligation of BTC, enforceable against BTC in
accordance with its terms except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors’ rights generally and by general equitable
principles. The execution, delivery and performance of this Agreement have been duly authorized by all necessary action on the part of BTC, its officers and directors; 
 (b) As of the Effective Date BTC owns or possesses adequate licenses or other rights necessary to make, use and sell all technology covered by the BTC Patents, and to grant the licenses herein and the granting of the
licenses to Auxilium hereunder does not violate any right known to BTC of any Third Party; 
 (c) BTC represents that to the best of its
knowledge, as of the Effective Date it is not aware that the development, manufacture, use or sale of the Enzyme or the Product pursuant to this Agreement may infringe or conflict with any Third Party right or Patent, and BTC is not aware of any
pending patent application that, if issued, would be infringed by the development, manufacture, use or sale of the Enzyme or the Product pursuant to this Agreement; 
 (d) The execution, delivery and performance of this Agreement by BTC does not conflict with any agreement, instrument or understanding, oral or written, to which it is a Party or by which it may be bound, and, to the
best of its knowledge, does not violate any material law or regulation of any court, governmental body or administrative or other agency having authority over it; 
  

 30 








 (e) BTC has disclosed to Auxilium all material information in its control pertaining to the suitability
of Enzyme as a pharmaceutical candidate; 
 (f) The Product has valid and effective Orphan Drug Designation under the applicable FDA
statutes, rules or regulations, effective, May 23, 1996, and March 12, 1996 BTC has no reason to believe such Orphan Drug Designation shall be terminated prior to the Effective Date. 
 (g) BTC is not currently a Party to, and during the Term will not enter into, any agreements, oral or written, that are inconsistent with its obligations
under this Agreement; 
 (h) BTC is duly organized and validly existing under the laws of the state of Delaware and has full legal power and
authority to enter into this Agreement; and 
 (i) BTC is not subject to any order, decree or injunction by a court of competent jurisdiction
which prevents or materially delays the consummation of the transactions contemplated by this Agreement. 
 9.2 Auxilium Represents and
Warrants. Auxilium hereby represents and warrants to BTC that: 
 (a) The execution, delivery and performance of this Agreement by
Auxilium does not conflict with any agreement, instrument or understanding, oral or written, to which it is a Party or by which it may be bound, and, to the best of its knowledge, does not violate any material law or regulation of any court,
governmental body or administrative or other agency having authority over it; 
 (b) Auxilium is not currently a Party to, and during the
Term will not enter into, any agreements, oral or written, that are inconsistent with its obligations under this Agreement; 
 (c) Auxilium
is duly organized and validly existing under the laws of the state of Delaware and has full legal power and authority to enter into this Agreement; and 
 (d) Auxilium is not subject to any order, decree or injunction by a court of competent jurisdiction which prevents or materially delays the consummation of the transactions contemplated by this Agreement. 

9.3 Disclaimer of Warranties. THE LIMITED WARRANTIES CONTAINED IN THIS ARTICLE ARE THE SOLE WARRANTIES GIVEN BY THE PARTIES AND ARE MADE
EXPRESSLY IN LIEU OF AND EXCLUDE ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, INFRINGEMENT OR OTHERWISE, AND ALL OTHER EXPRESS OR IMPLIED REPRESENTATIONS AND WARRANTIES PROVIDED BY COMMON LAW, STATUTE OR
OTHERWISE ARE HEREBY DISCLAIMED BY BOTH PARTIES. 
  

 31 








 ARTICLE 10 
 CONFIDENTIALITY 
 10.1 Confidentiality. During the Term, and for a period of five
(5) years thereafter, each Party hereto will maintain in confidence all information disclosed, and reasonably believed by the other party to be confidential whether orally or in writing, by the other Party hereto (“Confidential
Information”). Neither Party shall use, disclose or grant use of such Confidential Information except as required under this Agreement. Each Party shall use at least the same standard of care as it uses to protect its own Confidential
Information to ensure that its and its Affiliates’ employees, agents, consultants, and clinical investigators only make use of Confidential Information for the purpose of this Agreement and do not disclose or make any unauthorized use of such
Confidential Information. Each Party shall promptly notify the other upon discovery of any unauthorized use or disclosure of Confidential Information. Confidential Information shall not include any information which and to the extent: 
 (a) was already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the other Party; 

(b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the other Party; 
 (c) becomes generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of
the receiving Party in breach of this Agreement; 
 (d) was disclosed to the receiving Party, other than under an obligation of
confidentiality, by a Third Party who had no obligation to the other Party not to disclose such information; or 
 (e) was independently
developed by the receiving Party without reference to the disclosure by the other Party, as documented by written records. 
 10.2 Terms
of Agreement. The Parties agree that the material financial terms of the Agreement shall be considered the Confidential Information of both Parties. 
 10.3 Permitted Disclosure. Each Party may disclose the Confidential Information to the extent such disclosure is reasonably necessary in filing or prosecuting patent applications, prosecuting or defending
litigation, or complying with any applicable statute or governmental regulation provided such Party has given the disclosing Party prompt written notice allowing it to limit such disclosure. In addition, either Party may disclose Confidential
Information to its Affiliates and to its Sublicensees; provided, however, in connection with any such disclosure the disclosing Party shall secure confidential treatment of such Confidential Information. 
 10.4 Employee Obligations. The Parties shall undertake to ensure that all their employees who have access to Confidential Information of the other
Party are under obligations of confidentiality fully consistent with those provided in this Article. 
  

 32 








 10.5 Publication. No Party may publish confidential or proprietary information of the other Party,
without the consent of the other Party. The reviewing Party shall have thirty (30) days from receipt of the proposed oral disclosure or written publication to provide comments or proposed changes to the disclosing Party. The review period may
be extended for an additional two (2) months to permit the reviewing Party to file one or more patent applications as it deems appropriate. This Section 10.5 shall be inapplicable to the publication of information presented in
substantially the same form in which was previously published or disclosed to the public, and to any other disclosures which, on the advice of counsel, are required by law to be disclosed. 
 10.6 Prior Agreements. The obligations of Confidentiality and Nondisclosure set forth in this Section 10 supersede any and all prior and
contemporaneous communications, representations, agreements or understandings, whether oral or written concerning the subject matter of this Section 10. 
 ARTICLE 11 
 TERM AND TERMINATION 
 11.1 Term. 
 (a) Term. Unless
earlier terminated as provided herein, the Term shall commence as of the Effective Date and shall remain in full force and effect on a Product by Product and country by country basis until the later of (i) the last to expire valid claim of a
patent covering such Product, (ii) the expiration of the regulatory exclusivity period conveyed by Orphan Drug Designation with respect to such Product, and (iii) twelve (12) years (the “Term”). 
 (b) Accrued Obligations. Except where explicitly provided elsewhere herein, termination of this Agreement for any reason, or expiration of this
Agreement, will not affect: (i) obligations, including the payment of any royalties or other sums which have accrued as of the date of termination or expiration, and (ii) rights and obligations which, from the context thereof, are intended
to survive termination or expiration of this Agreement. 
 11.2 Termination for Insolvency. Either Party may terminate this Agreement
immediately upon delivery of written notice to the other Party (a) upon the institution by or against the other Party of insolvency, receivership or bankruptcy proceedings or any other proceedings for the settlement of the other Party’s
debts; provided, however with respect to involuntary proceedings, that such proceedings are not dismissed within one hundred and twenty (120) days; (b) upon the other Party’s making an assignment for the benefit of creditors; or
(c) upon the other Party’s dissolution or ceasing to do business. 
 11.3 Material Breach. Either Party may terminate this
Agreement upon ninety (90) days prior written notice to the other Party upon the material breach by the other Party of any of its obligations under this Agreement; provided, however, that such termination shall become effective only if the
other Party shall fail to remedy or cure the breach within such ninety (90) day period. 
 11.4 Termination by Auxilium. Auxilium
may terminate this Agreement in its entirety or on a country-by-country basis or on an Indication by Indication basis or on a Product by Product basis at any time upon ninety (90) days prior written notice to BTC. 
  

 33 








 11.5 Effect Of Termination. 
 (a) Effect On License. Upon the expiration or earlier termination of this Agreement, the rights licensed under this Agreement shall be treated as
follows: 
 (i) Upon the expiration of the Term or the termination of this Agreement by Auxilium pursuant to Section 11.2
or Section 11.3, Auxilium shall have a fully paid-up, perpetual, irrevocable, royalty-free, transferable, worldwide, non-exclusive right and license under the Licensed Technology existing as of the date of such expiration to make, have made,
use, offer to sell, and sell the Product in the Territory. 
 (ii) Upon termination of this Agreement by BTC pursuant to
Section 11.2 or 11.3, or by Auxilium pursuant to Section 11.4 all rights to Product shall revert to BTC. 
 (b) Ongoing
Obligations. 
 (i) Upon expiration or termination of this Agreement for any reason, each Party shall no later than thirty
(30) days after such termination return to the other Party or destroy any Confidential Information disclosed by the other Party, except for one copy which may be retained in its confidential files. 
 (ii) Upon termination of this Agreement by BTC pursuant to Sections 11.2 or 11.3 or by Auxilium pursuant to Section 11.4, Auxilium
shall assign and deliver to BTC all Regulatory Data and information (including registration dossiers) obtained for or in pursuing Regulatory Approvals, and all Regulatory Approvals (e.g., to BTC; designee in the Territory as permitted under the Law)
for Product in the Territory received as of such termination date. 
 11.6 Inventory. Notwithstanding the foregoing, upon early
termination of this Agreement pursuant to Section 11.2, 11.3 or 11.4, Auxilium shall have the right to sell all remaining Product in its inventory within six (6) months after the date of termination, but shall be bound to the royalty
payments provided by Article 7.4 herein. Thereafter, Auxilium agrees to destroy any remaining supply of Product or return it to BTC at BTC’s request and direction. 
 ARTICLE 12 
 INDEMNIFICATION 
 12.1 Auxilium. Auxilium shall defend BTC at Auxilium’ cost and expense, and will indemnify and hold BTC and their respective directors,
officers, employees, consultants, contractors, representatives, and agents harmless from and against any and all losses, costs, damages, fees, or expenses (including reasonable attorney’s fees and expenses) (“Losses”) incurred in
connection with or arising out of any Third Party claim (a “Third Party Claim”) directly relating to (i) any material breach by Auxilium of its representations or warranties or obligations pursuant to this Agreement, (ii) any
gross negligence or willful misconduct of Auxilium, its Affiliates, or their respective directors, officers, employees, contractors, consultants, agents, representatives, or sublicensees in the exercise of any of Auxilium’ rights or the
performance of any of Auxilium’ obligations under this Agreement, and (iii) the handling, 

  

 34 








 
packaging, storage, or Commercialization by Auxilium or any of its Affiliates or sublicensees of any Product in the Territory (excluding all intellectual
property infringement or related claims, which are covered in Section 12.2); provided that notwithstanding the foregoing, in all cases referred to in this Section 12.1, Auxilium shall have no liability to BTC for any Losses to the extent
that such Losses were caused by any item for which BTC is required to indemnify Auxilium pursuant to Section 12.2. 
 12.2 BTC.
BTC shall defend Auxilium and its Affiliates at BTC’s cost and expense, and will indemnify and hold Auxilium and its Affiliates and their respective directors, officers, employees, consultants, contractors, representatives, and agents harmless
from and against any and all Losses incurred in connection with or arising out of any Third Party Claim directly relating to (i) material breach by BTC of any of its representations, warranties or obligations pursuant to this Agreement,
(ii) gross negligence or willful misconduct of BTC in the exercise of any of its rights or the performance of any of its obligations under this Agreement, (iii) personal injury and other product liability resulting from BTC’s
Development, Manufacture, or Commercialization of any Product, (iv) intellectual property infringement or related claims, including any Third Party Claim and trade secret misappropriation liability relating to the Development, Manufacture, or
Commercialization of any Product, (v) any liability or other claims from the Manufacture, handling, packaging, storage, sale, or other disposition of any Product by BTC or any of its Affiliates or sublicensees, and (vi) any liability or
claims arising from Product supplied by or on behalf of BTC to Auxilium that was not Manufactured in accordance with current Good Manufacturing Practices, Good Clinical Practice and Good Laboratory Practices, the specifications or all Laws and
regulations except for such Losses that are indemnified pursuant to the Supply Agreement; provided that notwithstanding the foregoing, in all cases referred to in this Section 12.2, BTC shall have no liability to Auxilium for any Losses to the
extent (and only to the extent) that such Losses were caused by any item for which Auxilium is required to indemnify BTC pursuant to Section 12.1. 
 12.3 Claims Procedures. Each Party entitled to be indemnified by the other Party (an “Indemnified Party”) pursuant to Section 12.1 or 12.2 hereof shall give notice to the other Party (an
“Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any threatened or asserted claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such
claim or any litigation resulting therefrom; provided: 
 (a) That counsel for the Indemnifying Party, who shall conduct the defense of such
claim or any litigation resulting therefrom, shall be approved by the Indemnified Party (whose approval shall not unreasonably be withheld) and the Indemnified Party may participate in such defense at such Party’s expense (unless (i) the
employment of counsel by such Indemnified Party has been authorized by the Indemnifying Party; or (ii) the Indemnified Party shall have reasonably concluded that there may be a conflict of interest between the Indemnifying Party and the
Indemnified Party in the defense of such action, in each of which cases the Indemnifying Party shall pay the reasonable fees and expenses of one law firm serving as counsel for the Indemnified Party, which law firm shall be subject to approval, not
to be unreasonably withheld, by the Indemnifying Party). 
  

 35 








 (b) The failure of any Indemnified Party to give notice as provided herein shall not relieve the
Indemnifying Party of its obligations under this Agreement to the extent that the failure to give notice did not result in harm to the Indemnifying Party. 
 (c) No Indemnifying Party, in the defense of any such claim or litigation, shall, except with the approval of each Indemnified Party which approval shall not be unreasonably withheld, consent to entry of any judgment
or enter into any settlement which (i) would result in injunctive or other relief being imposed against the Indemnified Party; or (ii) does not include as an unconditional term thereof the giving by the claimant or plaintiff to such
Indemnified Party of a release from all liability in respect to such claim or litigation. 
 (d) Each Indemnified Party shall furnish such
information regarding itself or the claim in question as an Indemnifying Party may reasonably request in writing and shall be reasonably required in connection with the defense of such claim and litigation resulting therefrom. 
 12.4 Escrow. In the event of any Third Party Claim against Auxilium for which BTC is obligated to indemnify Auxilium in accordance with
Section 12.2, Auxilium shall be entitled, until a final un-appealable decision has been rendered or a settlement has been reached (a “Final Decision”), to pay an amount equal to fifty percent (50%) of all amounts due to BTC on
Net Sales of Products (such aggregate amount, the “Escrowed Amount”) into an escrow account maintained by a Third Party reasonably acceptable to BTC. To the extent that Auxilium incurs any Losses in connection with such Third Party Claim,
an amount equal to the amount of any such Losses shall be distributed to Auxilium out of such escrow account, with the remainder (if any) to be paid to BTC. In the event that the Escrow Amount is less than the amount of such Losses, BTC shall pay
the difference to Auxilium within thirty (30) days of such Final Decision. 
 12.5 Insurance. During the Term, each of Auxilium
and BTC shall maintain general liability and product liability insurance in the following amounts: (i) at all times prior to approval of a NDA for a Product, $3,000,000 per occurrence, and (ii) at all times after approval of a NDA for a
Product, $5,000,000. 
 12.6 Compliance. The Parties shall comply fully with all Laws and regulations in connection with their
respective activities under this Agreement. 
 ARTICLE 13 
 MISCELLANEOUS PROVISIONS 
 13.1 Dispute Resolution. In the event of any controversy or claim
arising out of relating to or in connection with any provision of this Agreement, or the rights or obligations hereunder, the Parties shall try to settle their differences amicably between themselves. Either Party may initiate such informal dispute
resolution by sending written notice of the dispute to the other Party, and within ten (10) business days after such notice appropriate representatives of the Parties shall meet for attempted resolutions by good faith negotiations. If such
representatives are unable to resolve such disputed matters, it shall be referred to the Chief Executive Officers of BTC and Auxilium, for discussion and resolution. If they are unable to resolve the dispute within thirty (30) days of
initiating such negotiations, the Parties agree first to submit the dispute 

  

 36 








 
to non-binding mediation before resorting to litigation or other mutually agreed dispute resolution mechanism. The dispute resolution procedures set forth
herein shall not limit a court from granting a temporary restraining order or a preliminary injunction in order to preserve the status quo of the Parties pending arbitration or to protect a Party’s trademark or confidential or proprietary
information. 
 13.2 Construction. Unless the context of this Agreement clearly requires otherwise, (a) references to the plural
include the singular, the singular the plural, the part the whole, (b) references to any gender include all genders, (c) “or” has the inclusive meaning frequently identified with the phrase “and/or,”
(d) “including” has the inclusive meaning frequently identified with the phrase “including but not limited to” or “including”, and (e) references to “hereunder” or “herein” relate to this
Agreement. The section and other headings contained in this Agreement are for reference purposes only and shall not control or affect the construction of this Agreement or the interpretation thereof in any respect. Section, subsection, and Schedule
references are to this Agreement unless otherwise specified. Each accounting term used herein that is not specifically defined herein shall have the meaning given to it under GAAP. 
 13.3 Governing Law; Jurisdiction. This Agreement shall be construed and the respective rights of the Parties determined according to the
substantive laws of the State of New York notwithstanding the provisions governing conflict of laws under such New York law to the contrary, except matters of intellectual property law which shall be determined in accordance with the intellectual
property laws relevant to the intellectual property in question. 
 13.4 Post-Closing Access to Information. BTC shall afford to
representatives of Auxilium reasonable access to offices, plants, properties, books and records of BTC relating to the Product, during normal business hours, in order that Auxilium may have an opportunity to make such reasonable investigations as it
desires with respect to Product. At all times after the Effective Date, each Party will permit the other Party and its representatives (including its counsel and auditors) during normal business hours, for a proper purpose to have reasonable access
to and examine and make copies of, at the expense of the copying Party, all books, records, files and documents in its possession which relate to the Product. 
 13.5 Section 365(n) of the Bankruptcy Code. All rights and licenses granted under or pursuant to any section of this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n)
of the Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101(35A) of the Bankruptcy Code. The Parties shall retain and may fully exercise all of their respective rights and elections under section
365(n) of the Bankruptcy Code. 
 13.6 Waiver. The failure on the part of Auxilium or BTC to exercise or enforce any rights conferred
upon it hereunder shall not be deemed to be a waiver of any such rights nor operate to bar the exercise or enforcement thereof at any time or times thereafter. The observance of any Term may be waived (either generally or in a particular instance
and either retroactively or prospectively) by the Party entitled to enforce such term, but any such waiver shall be effective only if in writing signed by the Party against whom such waiver is to be asserted. 
  

 37 








 13.7 Force Majeure. Neither Party shall be held liable or responsible to the other Party nor be
deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any Term, other than an obligation to make a payment, when such failure or delay is caused by or results from fire, floods, embargoes,
government regulations, prohibitions or interventions, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts, acts of God, or any other cause beyond the reasonable control of the affected Party.

 13.8 Severability. It is the intention of the Parties to comply with all Laws domestic or foreign in connection with the
performance of its obligations hereunder. In the event that any provision of this Agreement, or any part hereof, is found invalid or unenforceable, the remainder of this Agreement will be binding on the Parties hereto, and will be construed as if
the invalid or unenforceable provision or part thereof had been deleted, and the Agreement shall be deemed modified to the extent necessary to render the surviving provisions enforceable to the fullest extent permitted by law. 
 13.9 Government Acts. In the event that any act, regulation, directive, or law of a government, including its departments, agencies or courts,
should make impossible or prohibit, restrain, modify or limit any material act or obligation of Auxilium or BTC under this Agreement, the Party, if any, not so affected shall have the right, at its option, to suspend or terminate this Agreement as
to such country, if good faith negotiations between the Parties to make such modifications to this Agreement as may be necessary to fairly address the impact thereof, after a reasonable period of time are not successful in producing mutually
acceptable modifications to this Agreement. 
 13.10 Assignment. This Agreement may not be assigned or otherwise transferred by either
Party without the prior written consent of the other Party; provided, however, that either Party may assign this Agreement, without the consent of the other Party, in connection with the transfer or sale of all or substantially all of its assets or
business or in the event of its merger or consolidation with another company. In all cases the assigning Party shall provide the other Party with prompt notice of any such assignment. Any purported assignment in contravention of this Section shall,
at the option of the nonassigning Party, be null and void and of no effect. No assignment shall release either Party from responsibility for the performance of any accrued obligation of such Party hereunder. 
 13.11 Counterparts. This Agreement may be executed in duplicate, both of which shall be deemed to be originals, and both of which shall constitute
one and the same Agreement. 
 13.12 No Agency. Nothing herein contained shall be deemed to create an agency, joint venture,
amalgamation, partnership or similar relationship between BTC and Auxilium. Notwithstanding any of the provisions of this Agreement, neither Party shall at any time enter into, incur, or hold itself out to third Parties as having authority to enter
into or incur, on behalf of the other Party, any commitment, expense, or liability whatsoever, and all contracts, expenses and liabilities undertaken or incurred by one Party in connection with or relating to the development, manufacture or sale of
Enzymes or Product shall be undertaken, incurred or paid exclusively by that Party, and not as an agent or representative of the other Party. 
  

 38 








 13.13 Notice. All communications between the Parties with respect to any of the provisions of this
Agreement will be sent to the addresses set out below, or to other addresses as designated by one Party to the other by notice pursuant hereto, by internationally recognized courier or by prepaid certified, air mail (which shall be deemed received
by the other Party on the seventh business day following deposit in the mails), or by facsimile transmission or other electronic means of communication (which shall be deemed received when transmitted), with confirmation by letter given by the close
of business on or before the next following business day: 
 If to BTC, at: 
 Biospecifics Technologies Corp. 
 35 Wilbur
Street 
 Lynbrook, New York 11563 
 Attn:
                                        
         
 with a copy to: 
 Brown Raysman Millstein Felder & Steiner LLP 
 163 Madison Avenue 
 P.O. Box 1989 
 Morristown, New Jersey 07962-1989 
 Attn.: Leslie Gladstone Restaino, Esq. 
 If to Auxilium at: 
 Auxilium
Pharmaceuticals Inc. 
 160 West Germantown Pike 
 Norristown, PA 19401 
 Attn:
                                        
         
 with a copy to: 
 Morgan, Lewis & Bockius LLP 
 1701
Market Street 
 Philadelphia, PA 19103 
 Attn: Manya S. Deehr, Esq. 
 13.14 Headings. The paragraph headings are for convenience only and will not be deemed to
affect in any way the language of the provisions to which they refer. 
 13.15 Assurances. Neither Party will take any action, or fail
to act in a manner, which would prejudice the rights intended to be granted to the other Party pursuant to this Agreement. 
 13.16 Entire
Agreement. This Agreement contains the entire understanding of the Parties relating to the matters referred to herein, and may only be amended by a written document, duly executed on behalf of the respective Parties. 
  

 39 








 [Signature Page Follows] 
  

 40 








 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their duly authorized
representatives as of the Effective Date. 
  

			
	AUXILIUM PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Gerri Henwood

	Name:	 	Gerri Henwood
	Title:	 	CEO
	
	BIOSPECIFICS TECHNOLOGIES CORP.
		
	By:	 	 /s/ Edwin H. Wegman

	Name:	 	Edwin H. Wegman
	Title:	 	Pres.









 Schedule 1.7 BTC Patents 
 BIOSPECIFICS TECHNOLOGIES CORP. AND SUBSIDIARIES 
 PATENT APPLICATIONS AND EXISTING
PATENTS 
 1. U.S. Patent 5,393,792, patented February 28, 1995, inventors Dr. Harold Stern and Dr. David Yee, title: High Dosage
Topical Forms of Collagenase 
 2. U.S. Patent 5,422,103, patented June 6, 1995, inventors Dr. Harold Stern and Dr. David Yee, title: High
Dosage Topical Forms of Collagenase 
 3. U.S. Patent 5,514,370, patented May 7, 1995, inventors Dr. Harold Stern and Dr. David Yee, title:
High Dosage Forms of Collagenase (Method of Treatment with...). 
 Note: Foreign patent applications corresponding to the above U.S. applications have been
filed in [**] foreign countries (Australia, Canada, 9 countries of the European patent convention, (Austria, France, Germany, Ireland, Italy, Netherlands, Spain, Switzerland, United Kingdom, Hungary, [**], Russia). Patents have issued
in all countries except [**], where the application is pending. 
 4. U.S. application inventors [**]. US Patent Application # 10/172601
pending. 
 5. U.S. Patent 6.086.872, patented July 11, 2000, inventor Thomas L. Wegman, Amelioration of Dupuytren’s Disease. 
 Note: Foreign patents corresponding to the above patent have been granted in 4 countries. France (2,772,273 granted 4/25/03), Australia (733,208 granted 8/23/01), UK
(98050503 granted 10/10/01) and Sweden (9800806-3 granted 3/2/04). Patents have been filed in [**]. 
 6. U.S. Patent 6.022,539, patented
February 8, 2000, inventor Thomas L. Wegman, Amelioration of Peyronie’s Disease. 
 Note: Foreign patent application corresponding to the above
application have been filed in [**] countries. [**], France, [**]. Corresponding patent French Patent 0006863 has issued. 
 7. U.S.
Patent 5,173,295, patented December 22, 1992, inventor Peter Wehling, title: Method of Enhancing the Regeneration of Injured Nerves and Adhesive Pharmaceutical Formulation Therefor. 
 8. U.S. Patent 5,279,825, patented January 18, 1994, inventor Peter Wehling, title: Method of Enhancing the Regeneration of Injured Nerves and Adhesive Pharmaceutical Formulation Therefor. 
 Note: Foreign patent application corresponding to the above two cases filed in [**]. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED PURSUANT TO AN ORDER GRANTING CONFIDENTIAL TREATMENT ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.









 9. European Patent Office Patent EPO721781B1 June 2002 – inventors Edwin H. Wegman, Burton Bronsther, and Erwin T.
Jacob, title: Reduction of Adipose Tissue Using Collagenase. This patent is being extended into [**] additional countries. 
 Patents licensed to Advance Biofactures Corp. 
 10. US Patent 5,851,522, patented December 22, 1998 inventor Dr. I. M
Herman titled “Enhancing Keratinocyte Migration. EPO, (9 countries), Canada 
 11. US Patent 5,718,897, patented on February 17, 1998. Inventor
Dr. Ira Herman, Title: Enhancing Keratinocyte Migration and Proliferation. 
 Note: Foreign patent application corresponding to the above case has been
filed in [**]. 
 Updated: May 24, 2004 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED PURSUANT TO AN ORDER GRANTING CONFIDENTIAL TREATMENT ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.









 Schedule 1.16 
 Cost of Goods 
 The cost of Enzyme or a Product manufactured by BTC shall mean the fully allocated cost of
manufacturing, which shall include: 
 1. Materials cost, which means the price paid for raw material components and finished goods which are purchased from
outside vendors as well as any freight and duty where applicable. 
 2. Direct labor costs, which means the employment costs including, salary and employee
benefits within the relevant manufacturing operating unit. 
 3. Direct and factory overheads, which means the cost of specific activities that are provided
by support functions. Overhead costs includes expenses associated with quality assurance testing, batch review, equipment maintenance costs, manufacturing energy and utilities, waste removal, storage, transportation, insurance, management and
administrative expenses, general facilities costs, environmental engineering, interest expense and property taxes. 
 Cost of Goods shall be calculated in
accordance with U.S. Generally Accepted Accounting Principles. BTC’s Cost of Goods for Enzyme or Product shall in no event exceed [**]% of the cost of Enzyme or Product as supplied, or as could be supplied, by a Third Party, as measured
at the request of Auxilium and no more frequently than once per calendar year. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED PURSUANT TO AN ORDER GRANTING CONFIDENTIAL TREATMENT ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.









 Schedule 1.21 
 Enzyme 
 Schedule 1.2.1 Enzyme 
 The enzyme is [**]. 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED PURSUANT TO AN ORDER GRANTING CONFIDENTIAL TREATMENT ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.









 Schedule 3.2 
 Clinical Trials 
 Schedule 3.2 Clinical Trials 
 Dupuytren’s Disease 
 [**] 
 Peyronie’s Disease 
 [**] 
  

	**	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED PURSUANT TO AN ORDER GRANTING CONFIDENTIAL TREATMENT ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.